{"id":"NCT00378378","sponsor":"Organon and Co","briefTitle":"Study of Nasonex® for the Treatment of Nasal Polyps in Pediatric Subjects Between Ages of 6 and Less Than 18 Years Old (P04292)","officialTitle":"Study of Nasonex® for the Treatment of Nasal Polyps in Pediatric Subjects Between Ages of 6 and Less Than 18 Years Old","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-07","primaryCompletion":"2008-06","completion":"2008-06","firstPosted":"2006-09-20","resultsPosted":"2010-07-20","lastUpdate":"2024-05-20"},"enrollment":127,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Nasal Polyps"],"interventions":[{"type":"DRUG","name":"Mometasone Furoate Nasal Spray (MFNS)","otherNames":["Nasonex"]},{"type":"DRUG","name":"Placebo nasal spray","otherNames":[]}],"arms":[{"label":"MFNS 100 mcg QD for subjects 6 to less than 12 years","type":"EXPERIMENTAL"},{"label":"Placebo QD for subjects 6 to less than 12 years","type":"PLACEBO_COMPARATOR"},{"label":"MFNS 200 mcg QD for subjects 12 to less than 18 years","type":"EXPERIMENTAL"},{"label":"MFNS 200 mcg BID for subjects 12 to less than 18 years","type":"EXPERIMENTAL"},{"label":"Placebo QD for subjects 12 to less than 18 years","type":"PLACEBO_COMPARATOR"},{"label":"MFNS 100 mcg BID for subjects 6 to less than 12 years","type":"EXPERIMENTAL"},{"label":"Placebo BID for subjects 6 to less than 12 years","type":"PLACEBO_COMPARATOR"},{"label":"Placebo BID for subjects 12 to less than 18 years","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of Nasonex® (Mometasone Furoate Nasal Spray(MFNS)) in the treatment of nasal polyps in pediatric subjects between the ages of 6 and less than 18 years old. Safety will be the primary focus of this study.","primaryOutcome":{"measure":"Change From Baseline 24-hour Urinary Free Cortisol Level","timeFrame":"Baseline to Endpoint","effectByArm":[{"arm":"MFNS 100 or 200 mcg BID for Subjects 6 to Less Than 18 Years","deltaMin":49.5,"sd":32.4},{"arm":"MFNS 100 or 200 mcg QD for Subjects 6 to Less Than 18 Years","deltaMin":39.6,"sd":32.4},{"arm":"Pooled Placebo","deltaMin":49.8,"sd":32.4}],"pValues":[{"comp":"OG000 vs OG001","p":"0.258"},{"comp":"OG000 vs OG002","p":"0.735"},{"comp":"OG001 vs OG002","p":"0.194"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":14},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["23331528"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":50},"commonTop":["HEADACHE","NASOPHARYNGITIS","EPISTAXIS","INFLUENZA","PYREXIA"]}}